Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Entrada Therapeutics (TRDA) Tax Provisions (2023 - 2025)

Historic Tax Provisions for Entrada Therapeutics (TRDA) over the last 3 years, with Q3 2025 value amounting to $700000.0.

  • Entrada Therapeutics' Tax Provisions rose 13684.21% to $700000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$929000.0, marking a year-over-year decrease of 10432.66%. This contributed to the annual value of $900000.0 for FY2024, which is 9519.77% down from last year.
  • Entrada Therapeutics' Tax Provisions amounted to $700000.0 in Q3 2025, which was up 13684.21% from $200000.0 recorded in Q2 2025.
  • In the past 5 years, Entrada Therapeutics' Tax Provisions registered a high of $18.7 million during Q4 2023, and its lowest value of -$17.4 million during Q3 2023.
  • Moreover, its 3-year median value for Tax Provisions was $1.3 million (2024), whereas its average is $2.1 million.
  • Its Tax Provisions has fluctuated over the past 5 years, first crashed by 10975.94% in 2024, then surged by 13684.21% in 2025.
  • Entrada Therapeutics' Tax Provisions (Quarter) stood at $18.7 million in 2023, then plummeted by 109.76% to -$1.8 million in 2024, then surged by 138.27% to $700000.0 in 2025.
  • Its last three reported values are $700000.0 in Q3 2025, $200000.0 for Q2 2025, and -$1.8 million during Q4 2024.